Intensity Therapeutics Announces Reverse Stock Split

Core Viewpoint - Intensity Therapeutics, Inc. announced a 1-for-25 reverse stock split to increase the per share trading price and regain compliance with Nasdaq's minimum bid price requirement [1] Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies using proprietary non-covalent conjugation technology [1] - The company’s lead product candidate, INT230-6, is designed for direct intratumoral injection and combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, with a diffusion enhancer [1] Reverse Stock Split Details - The reverse stock split will take effect on February 18, 2026, with trading on a split-adjusted basis starting February 19, 2026 [1] - The number of outstanding shares will decrease from approximately 63,346,579 to about 2,533,863 shares [1] - No fractional shares will be issued; stockholders will receive cash payments for any fractional shares [1] Clinical Trials and Product Development - INT230-6 has shown the ability to kill tumors and elicit an immune response within days of injection, representing a potential shift in cancer treatment paradigms [1] - The company has completed two clinical studies with over 200 patients, including a Phase 1/2 study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer [1] - A Phase 3 trial in soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group are also underway [1]